Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Published:2016-07 Issue:7 Volume:17 Page:943-955
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Weber Jeffrey S,Gibney Geoff,Sullivan Ryan J,Sosman Jeffrey A,Slingluff Craig L,Lawrence Donald P,Logan Theodore F,Schuchter Lynn M,Nair Suresh,Fecher Leslie,Buchbinder Elizabeth I,Berghorn Elmer,Ruisi Mary,Kong George,Jiang Joel,Horak Christine,Hodi F Stephen

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

2. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates;Wang;Cancer Immunol Res,2014

3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015

5. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application;Okazaki;Nat Immunol,2013

Cited by 293 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11

2. Magnetic Miniature Soft Robot with Reprogrammable Drug‐Dispensing Functionalities: Toward Advanced Targeted Combination Therapy;Advanced Materials;2024-09-09

3. Robust identification of perturbed cell types in single-cell RNA-seq data;Nature Communications;2024-09-01

4. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells;Cancer Cell;2024-09

5. Exploiting temporal aspects of cancer immunotherapy;Nature Reviews Cancer;2024-06-17